PHF5A promotes esophageal squamous cell carcinoma progression via stabilizing VEGFA

• Published in: Biology direct 2024-03, Vol.19 (1), p.19-14, Article 19
• Main Authors: Chang, Zhiwei, Jia, Yongxu, Gao, Ming, Song, Lijie, Zhang, Weijie, Zhao, Ruihua, Yu, Dandan, Liu, Xiaolei, Li, Jing, Qin, Yanru
• Format: Article
• Language: English
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Animals; Apoptosis; Assaying; Cancer; Cancer therapies; Cell cycle; Cell growth; Cell Line, Tumor; Cell migration; Cell Movement - genetics; Cell proliferation; Cell Proliferation - genetics; Cell viability; ESCC; Esophageal cancer; Esophageal carcinoma; Esophageal Neoplasms - genetics; Esophageal Neoplasms - metabolism; Esophageal Neoplasms - pathology; Esophageal Squamous Cell Carcinoma - genetics; Esophageal Squamous Cell Carcinoma - metabolism; Esophageal Squamous Cell Carcinoma - pathology; Esophagus; Gene Expression Regulation, Neoplastic; Genes; Growth factors; Homeobox; Humans; Immunohistochemistry; Immunoprecipitation; MDM2 protein; Medical prognosis; Mice; Molecular modelling; PHF5A; Phosphatidylinositol 3-Kinases - genetics; PI3K/AKT signaling; Proteins; Proto-Oncogene Proteins c-akt - genetics; RNA-Binding Proteins - genetics; RNA-mediated interference; Squamous cell carcinoma; Stem cells; Survival analysis; Therapeutic targets; Trans-Activators - genetics; Tumors; Ubiquitination; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - genetics; Vascular Endothelial Growth Factor A - metabolism; VEGFA; Wound healing; Xenotransplantation
• ISSN: 1745-6150; 1745-6150
• DOI: 10.1186/s13062-023-00440-3

Esophageal squamous cell carcinoma (ESCC) is the main subtype of esophageal cancer. Current therapeutic effect is far from satisfaction. Hence, identifying susceptible genes and potential targets is necessary for therapy of ESCC patients. Plant homeodomain (PHD)-finger domain protein 5 A (PHF5A) expression in ESCC tissues was examined by immunohistochemistry. RNA interference was used for in vitro loss-of-function experiments. In vivo assay was performed using xenograft mice model by subcutaneous injection. Besides, microarray assay and co-immunoprecipitation experiments were used to study the potential downstream molecules of PHF5A in ESCC. The molecular mechanism between PHF5A and vascular endothelial growth factor A (VEGFA) was explored by a series of ubiquitination related assays. We found that PHF5A was highly expressed in ESCC tissues compared to normal tissues and that was correlated with poor prognosis of ESCC. Loss-of-function experiments revealed that PHF5A silence remarkably inhibited cell proliferation, migration, and induced apoptosis as well as cell cycle arrest. Consistently, in vivo assay demonstrated that PHF5A deficiency was able to attenuate tumor growth. Furthermore, molecular studies showed that PHF5A silencing promoted VEGFA ubiquitination by interacting with MDM2, thereby regulating VEGFA protein expression. Subsequently, in rescue experiments, our data suggested that ESCC cell viability and migration promoted by PHF5A were dependent on intact VEGFA. Finally, PI3K/AKT signaling rescue was able to alleviate shPHF5A-mediated cell apoptosis and cell cycle arrest. PHF5A is a tumor promoter in ESCC, which is dependent on VEGFA and PI3K/AKT signaling. PHF5A might serve as a potential therapeutic target for ESCC treatment.